We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-10.7%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.35B
AUM Growth
-$119M
Cap. Flow
-$74.1M
Cap. Flow %
-3.15%
Top 10 Hldgs %
36.4%
Holding
125
New
15
Increased
30
Reduced
16
Closed
20

Top Buys

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$76.3M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$48.9M
3
EDIT icon
Editas Medicine
EDIT
+$44.9M
4
VTRS icon
Viatris
VTRS
+$37.5M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$36M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$84.3M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$53.5M
3
CRL icon
Charles River Laboratories
CRL
+$30.3M
4
GHDX
Genomic Health, Inc.
GHDX
+$28.5M
5
PCRX icon
Pacira BioSciences
PCRX
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 69.81%
2 Financials 4.2%
3 Technology 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
51
DELISTED
Acceleron Pharma
XLRN
$9.33M 0.4%
353,491
+140,000
+66% +$4.07M
NSTG
52
DELISTED
NanoString Technologies, Inc.
NSTG
$9.23M 0.39%
606,222
-274,400
-31% -$3.88M
EPIX
53
DELISTED
ESSA Pharma
EPIX
$8.41M 0.36%
129,361
+36,397
+39% +$2.37M
LOXO
54
DELISTED
Loxo Oncology, Inc
LOXO
$6.86M 0.29%
251,000
– –
SEM
55
DELISTED
Select Medical
SEM
$6.6M 0.28%
+1,037,684
New +$5.57M
FOMX
56
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$6.19M 0.26%
948,934
– –
GNCA
57
DELISTED
Genocea Biosciences, Inc.
GNCA
$6.09M 0.26%
98,407
-6,250
-6% -$199K
ARLZ
58
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$5.84M 0.25%
+1,644,583
New +$8.48M
RIGL icon
59
Rigel Pharmaceuticals
RIGL
$748M
$4.99M 0.21%
239,786
– –
NEOS
60
DELISTED
Neos Therapeutics, Inc
NEOS
$4.95M 0.21%
458,332
– –
ELGX
61
DELISTED
Endologix Inc
ELGX
$4.76M 0.2%
+56,990
New +$4.7M
ABMD
62
DELISTED
Abiomed Inc
ABMD
$4.72M 0.2%
+49,797
New +$4.2M
OXFD
63
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$4.6M 0.2%
464,541
-55,129
-11% -$565K
CASM
64
DELISTED
CAS Medical Systems, Inc.
CASM
$4.54M 0.19%
3,200,000
– –
EGLT
65
DELISTED
Egalet Corporation
EGLT
$4.1M 0.17%
597,123
+120,000
+25% +$941K
ARCT icon
66
Arcturus Therapeutics
ARCT
$174M
$4.05M 0.17%
152,845
– –
MYOK
67
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$4.01M 0.17%
374,800
-200
-0.1% -$1.82K
EYPT icon
68
EyePoint Inc
EYPT
$1.15B
$4M 0.17%
149,282
+27,071
+22% +$856K
SCYX icon
69
SCYNEXIS
SCYX
$42.2M
$3.42M 0.15%
10,600
+1,896
+22% +$718K
STDY
70
DELISTED
SteadyMed Ltd
STDY
$3.31M 0.14%
1,346,744
– –
ATXS
71
DELISTED
Astria Therapeutics
ATXS
$3.24M 0.14%
10,726
– –
TNXP icon
72
Tonix Pharmaceuticals
TNXP
$197M
– –
0
– –
ACUR
73
DELISTED
Acura Pharmaceuticals
ACUR
$2.9M 0.12%
1,025,641
– –
TCON
74
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$2.78M 0.12%
1,985
-440
-18% -$626K
ARDX icon
75
Ardelyx
ARDX
$1.3B
$2.14M 0.09%
+275,000
New +$2.71M
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2016 Portfolio in Review

As of Q1 2016, Deerfield Management held 125 positions worth $2.35B, down 4.8% from $2.47B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Deerfield Management withdrew a net $74.1M in Q1 2016, closing 20 positions and reducing 16 holdings. Its most notable exit was DYAX CORPORATION, an estimated $84.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 68% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in AveXis, Inc. Common Stock worth $60.9M.

  • Deerfield Management's largest Q1 2016 buy was AveXis, Inc. Common Stock: 2,236,701 shares worth $60.9M.
  • Deerfield Management added most to Portola Pharmaceuticals, Inc. in Q1 2016, an estimated $76.3M increase.
  • Deerfield Management's biggest Q1 2016 reduction was Adeptus Health Inc, cutting an estimated $18.2M.
  • Deerfield Management fully exited DYAX CORPORATION in Q1 2016, selling an estimated $84.3M.
  • Deerfield Management's ten largest holdings make up 36% of its $2.35B portfolio in Q1 2016.
  • Deerfield Management opened 15 new positions and closed 20 in Q1 2016.
  • Deerfield Management's portfolio value fell 4.8% quarter-over-quarter to $2.35B.

Based on Deerfield Management's 13F filing for Q1 2016, filed 16 May 2016.